Frontier Bio Secures $1B GSK Deal for Kidney Therapies

Frontier Bio Grants GSK Global Rights in $1B Agreement

Frontier Biotechnologies secured a landmark licensing deal with pharmaceutical giant GSK on February 24, 2026, potentially valued at up to $1 billion. The agreement gives GSK exclusive worldwide rights to develop and commercialize two of Frontier's small interfering RNA (siRNA) therapies. These experimental treatments are designed to target specific kidney diseases, marking a significant investment by GSK into advanced RNA-based therapeutics.

Deal Validates Frontier's Platform, Expands GSK's Pipeline

For Frontier Biotechnologies, the partnership represents a major validation of its underlying technology platform and provides a substantial source of non-dilutive funding. The potential $1 billion payout underscores the high value placed on its siRNA candidates. For GSK, the deal strategically expands its drug development pipeline into the high-growth field of renal medicine, using a next-generation therapeutic approach. This move allows GSK to acquire promising assets without the upfront costs and risks associated with early-stage discovery.